首页> 外文期刊>Advances in therapy. >Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.
【24h】

Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.

机译:玻璃体内贝伐单抗的手术结局和新生血管性青光眼的滤过手术。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: The purpose of this study was to evaluate the surgical outcome of a trabeculectomy with mitomycin C (MMC) in neovascular glaucoma after an adjunctive treatment with intravitreal bevacizumab (Avastin(R); Genentech Inc, San Francisco, CA, USA) injection (IVB). METHODS: Six patients with NVG presented at the Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand. After adequate panretinal photocoagulation (PRP) and maximal antiglaucoma medication therapy, these patients received IVB (1.25 mg in 0.05 ml) due to persistent neovascularisation of the iris (NVI). A fornix-based conjunctival flap trabeculectomy with MMC was performed within 4 weeks following administration of IVB. RESULTS: Three patients with proliferative diabetic retinopathy (PDR) and three patients with central retinal vein occlusion (CRVO) were enrolled in the study (mean age, 57 years). Absolute regression of NVI was observed within 1 week after IVB in four patients. In two patients NVI was reduced but still persisted. Mean intraocular pressure (IOP) decreased from 39.8 mmHg pre-operatively to 7.5 mmHg on the first postoperative day. No intra-operative complications were noted. Two patients had postoperative hyphema, which resolved spontaneously within 1 week. During the mean follow up of 24.7 weeks, five patients had controlled IOP (range, 2-16 mmHg) without antiglaucoma medication. Two patients with PDR had improved visual acuity whereas two patients with CRVO lost pre-operative light perception. Recurrent NVI was subsequently detected in one patient who had uncontrolled IOP. This patient underwent transscleral diode laser cyclophotocoagulation and additional PRP. All patients were symptom-free at last visit. CONCLUSION: IVB is an effective modality to reduce intra-operative complications during trabeculectomy for neovascular glaucoma. The short-term outcomes following trabeculectomy with MMC are favourable.
机译:简介:本研究的目的是评估玻璃体腔注射贝伐单抗(Avastin®; Genentech Inc,旧金山,加利福尼亚州,美国)的辅助治疗后,丝裂霉素C(MMC)小梁切除术在新生血管性青光眼中的手术效果( IVB)。方法:6例NVG患者在泰国Mahidol大学Siriraj医院眼科内科就诊。经过充分的视网膜光凝(PRP)和最大抗青光眼药物治疗后,这些患者由于虹膜(NVI)持续新生血管而接受了IVB(1.25 mg,0.05 ml)。静脉注射IVB后4周内进行了基于穹ni的结膜瓣小梁切除术,伴MMC。结果:该研究纳入了3例糖尿病性增生性视网膜病变(PDR)患者和3例视网膜中央静脉阻塞(CRVO)患者(平均年龄57岁)。 IVB后1周内观察到4例患者的NVI绝对消退。在两名患者中,NVI减少但仍持续存在。术后第一天,平均眼压(IOP)从术前的39.8 mmHg降至7.5 mmHg。没有发现术中并发症。两名患者术后出现眼前湿疹,在1周内自然消退。在平均24.7周的随访中,有5例患者在未使用抗青光眼药物的情况下控制了IOP(范围2-16 mmHg)。两名PDR患者的视力得到改善,而两名CRVO患者术前失去了光感。随后在一名IOP失控的患者中发现了复发性NVI。该患者接受了巩膜二极管激光环光凝术和其他PRP。所有患者在最后一次访视时均无症状。结论:IVB是减少小梁切除术中新生血管性青光眼术中并发症的有效方法。 MMC小梁切除术后的短期结果是有利的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号